Windtree to Present at the H.C. Wainwright Global Life Sciences Conference
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing late-stage interventions for acute cardiovascular and pulmonary disorders, including istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A live audio webcast will be available on the company's website, with a replay for 30 days. For further details, visit www.windtreetx.com.
- None.
- None.
WARRINGTON, Pa., March 8, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference and be available for 1x1 meetings. Details are as follows:
H.C. Wainwright Global Life Sciences Conference | |
Date: | March 9-10, 2021 |
Time: | available for 1x1 meetings |
Webcast: | To register, click on the link HERE |
A live audio webcast will be available via the events page of the Windtree website at http://windtreetx.investorroom.com/events. A replay of the presentation will be archived on the Windtree website for 30 days for those unable to listen live.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
For more information, please visit the Company's website at www.windtreetx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/windtree-to-present-at-the-hc-wainwright-global-life-sciences-conference-301241442.html
SOURCE Windtree Therapeutics, Inc.
FAQ
When is Windtree Therapeutics presenting at the H.C. Wainwright Global Life Sciences Conference?
Who will represent Windtree Therapeutics at the conference?
What is the focus of Windtree Therapeutics?
Where can I listen to the Windtree Therapeutics presentation?
What products is Windtree Therapeutics developing?
